Literature DB >> 18299854

[Scleroderma in childhood and adolescence. New aspects on classification, etiology and therapy].

H J Girschick1.   

Abstract

From a clinical point of view scleroderma is classified as either localized scleroderma or systemic scleroderma. However, as this didactic separation does not always reflect the clinical picture in patients, various groups have attempted to make new classification methods. This current review focuses on the clinical presentation in this respect, recently developed aspects of etiology and molecular pathogenesis in addition to modern aspects of therapeutic strategies.

Entities:  

Mesh:

Year:  2008        PMID: 18299854     DOI: 10.1007/s00393-007-0253-6

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  55 in total

1.  Increased expression of basic fibroblast growth factor in skin of patients with systemic sclerosis.

Authors:  A Lawrence; D Khanna; R Misra; A Aggarwal
Journal:  Dermatol Online J       Date:  2006-01-27

2.  Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.

Authors:  C P Denton; M Humbert; L Rubin; C M Black
Journal:  Ann Rheum Dis       Date:  2006-06-22       Impact factor: 19.103

3.  Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis.

Authors:  C M Artlett; J B Smith; S A Jimenez
Journal:  N Engl J Med       Date:  1998-04-23       Impact factor: 91.245

Review 4.  Scleroderma epidemiology.

Authors:  M D Mayes
Journal:  Rheum Dis Clin North Am       Date:  1996-11       Impact factor: 2.670

Review 5.  Adult stem cells in the treatment of autoimmune diseases.

Authors:  J M van Laar; A Tyndall
Journal:  Rheumatology (Oxford)       Date:  2006-06-15       Impact factor: 7.580

6.  Significant elevation of IgG anti-WRN (RecQ3 RNA/DNA helicase) antibody in systemic sclerosis.

Authors:  Makoto Goto; Masako Okawa-Takatsuji; Shinichi Aotsuka; Hidenori Nakai; Masatosi Shimizu; Hideyuki Goto; Akira Shimamoto; Yasuhiro Furuichi
Journal:  Mod Rheumatol       Date:  2006       Impact factor: 3.023

7.  Evaluation of oral methotrexate in the treatment of systemic sclerosis.

Authors:  M Krishna Sumanth; Vinod K Sharma; Binod K Khaitan; Anu Kapoor; Trilokraj Tejasvi
Journal:  Int J Dermatol       Date:  2007-02       Impact factor: 2.736

8.  The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis.

Authors:  Francesco Zulian; Patricia Woo; Balu H Athreya; Ronald M Laxer; Thomas A Medsger; Thomas J A Lehman; Marco Matucci Cerinic; Giorgia Martini; Angelo Ravelli; Ricardo Russo; Ruben Cuttica; Sheila Knupp Feitosa de Oliveira; Christopher P Denton; Franco Cozzi; Ivan Foeldvari; Nicolino Ruperto
Journal:  Arthritis Rheum       Date:  2007-03-15

9.  The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study).

Authors:  Fredrick M Wigley; Joao A C Lima; Maureen Mayes; David McLain; J Lincoln Chapin; Clive Ward-Able
Journal:  Arthritis Rheum       Date:  2005-07

10.  Neuroimaging findings in scleroderma en coup de sabre.

Authors:  S Appenzeller; M A Montenegro; S San Juan Dertkigil; P D Sampaio-Barros; J F Marques-Neto; A M Samara; F Andermann; F Cendes
Journal:  Neurology       Date:  2004-05-11       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.